Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF V600E MAP2K1 P124S |
| Therapy | Selumetinib |
| Indication/Tumor Type | melanoma |
| Response Type | decreased response |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600E MAP2K1 P124S | melanoma | decreased response | Selumetinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, patient-derived melanoma cells harboring BRAF V600E and MAP2K1 P124S demonstrated decreased sensitivity to Koselugo (selumetinib) compared to cells harboring BRAF V600E alone in culture (PMID: 22197931). | 22197931 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (22197931) | Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. | Full reference... |